2. Academic Validation
  3. Fenretinide prevents lipid-induced insulin resistance by blocking ceramide biosynthesis

Fenretinide prevents lipid-induced insulin resistance by blocking ceramide biosynthesis

  • J Biol Chem. 2012 May 18;287(21):17426-17437. doi: 10.1074/jbc.M112.359950.
Benjamin T Bikman 1,  Yuguang Guan 2,  Guanghou Shui 3,  M Mobin Siddique 2,  William L Holland 4,  Ji Yun Kim 5,  Gemma Fabriàs 6,  Markus R Wenk 7,  Scott A Summers 8
Affiliations

Affiliations

  • 1 Department of Physiology and Developmental Biology, Brigham Young University, Provo, Utah 84602; Program in Cardiovascular and Metabolic Diseases, Duke-National University of Singapore Graduate Medical School, Singapore 169857. Electronic address: benjamin_bikman@byu.edu.
  • 2 Program in Cardiovascular and Metabolic Diseases, Duke-National University of Singapore Graduate Medical School, Singapore 169857.
  • 3 Department of Biochemistry and, National University of Singapore, Singapore 119077; Life Sciences Institute, National University of Singapore, Singapore 119077.
  • 4 Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas, Texas 75390.
  • 5 National University of Singapore High School of Mathematics and Science, Singapore 129957.
  • 6 Research Unit on BioActive Molecules (RUBAM), Departament de Química Orgànica Biològica, Institut d'Investigacions Químiques i Ambientals de Barcelona, Consejo Superior de Investigaciones Científicas (CSIC), 08034 Barcelona, Spain.
  • 7 Department of Biochemistry and, National University of Singapore, Singapore 119077; Life Sciences Institute, National University of Singapore, Singapore 119077; Department of Biological Sciences, National University of Singapore, Singapore 169857.
  • 8 Program in Cardiovascular and Metabolic Diseases, Duke-National University of Singapore Graduate Medical School, Singapore 169857; Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, North Carolina 27710.
PMID: 22474281 DOI: 10.1074/jbc.M112.359950
Abstract

Fenretinide is a synthetic retinoid that is being tested in clinical trials for the treatment of breast Cancer and Insulin resistance, but its mechanism of action has been elusive. Recent in vitro data indicate that fenretinide inhibits dihydroceramide desaturase, an Enzyme involved in the biosynthesis of lipotoxic ceramides that antagonize Insulin action. Because of this finding, we assessed whether fenretinide could improve Insulin sensitivity and glucose homeostasis in vitro and in vivo by controlling ceramide production. The effect of fenretinide on Insulin action and the cellular lipidome was assessed in a number of lipid-challenged models including cultured myotubes and isolated muscles strips incubated with exogenous fatty acids and mice fed a high-fat diet. Insulin action was evaluated in the various models by measuring glucose uptake or disposal and the activation of Akt/PKB, a serine/threonine kinase that is obligate for insulin-stimulated anabolism. The effects of fenretinide on cellular lipid levels were assessed by LC-MS/MS. Fenretinide negated lipid-induced Insulin resistance in each of the model systems assayed. Simultaneously, the drug depleted cells of ceramide, while promoting the accumulation of the precursor dihydroceramide, a substrate for the reaction catalyzed by Des1. These data suggest that fenretinide improves Insulin sensitivity, at least in part, by inhibiting Des1 and suggest that therapeutics targeting this Enzyme may be a viable therapeutic means for normalizing glucose homeostasis in the overweight and diabetic.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z